Naohiro Nishida1, Makoto Yamsaki2, Kazuki Odagiri1, Kotaro Yamashita1, Koji Tanaka1, Daisuke Sakai3, Tomoki Makino1, Tsuyoshi Takahashi1, Yukinori Kurokawa1, Taroh Satoh3, Masaki Mori4, Yuichiro Doki1. 1. Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan. 2. Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan myamasaki@gesurg.med.osaka-u.ac.jp. 3. Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan. 4. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Abstract
BACKGROUND/AIM: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. PATIENTS AND METHODS: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. RESULTS: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). CONCLUSION: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC. Copyright
BACKGROUND/AIM: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. PATIENTS AND METHODS: Ten unresectable or recurrence ESCCpatients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. RESULTS: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). CONCLUSION: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC. Copyright
Authors: M Honda; A Miura; Y Izumi; T Kato; T Ryotokuji; K Monma; J Fujiwara; H Egashira; T Nemoto Journal: Dis Esophagus Date: 2010-11 Impact factor: 3.429
Authors: T Iizuka; T Kakegawa; H Ide; N Ando; H Watanabe; O Tanaka; I Takagi; K Isono; K Ishida; M Arimori Journal: Jpn J Clin Oncol Date: 1992-06 Impact factor: 3.019